CureX announced a donation of 20% of CUX tokens to the BioV Foundation to promote future medical innovations

ChainCatcher news, CureX announced that it will donate 20% of its CUX tokens to the BioV Foundation.

CureX expressed gratitude for the technical support and funding assistance from Chulalongkorn University in Thailand, the Thai Royal Family, and Biov Laboratory in California, USA. The BioV Foundation will authorize its TRC-T biotechnology products and therapies to CureX, which has received legal certification in the United States, demonstrating significant efficacy in the treatment of malignant synovial sarcoma. CureX will promote advancements in DeSci medical technology through this authorization.

At the same time, the BioV Foundation suggested that CureX airdrop the donated CUX tokens to community members supporting DeSci and biotechnology, and continue to contribute to the advancement of global biotechnology development.